Navigation Links
Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
Date:5/27/2009

;1%-33%), and hepatotoxicity (approx 5%)--and severe adverse experiences (NCI Grades 3/4), including severe fluid retention (e.g., pleural effusion, pulmonary edema, and ascites) and superficial edema (1.3%-11%), hemorrhage (1.8%-19%), and musculoskeletal pain (2%-9%) were reported among patients receiving Gleevec*. Severe fluid retention appears to be dose-related, was more common in the advanced-phase studies (where the dosage was 600 mg/day), and is more common in the elderly.

In HES/CEL patients, instances of Grade 3 leukopenia, neutropenia, lymphopenia, and anemia were reported.

For DFSP, severe (NCI Grades 3/4) lab abnormalities included anemia (17%), thrombocytopenia (17%), neutropenia (8%), and increased creatinine (8%).

In GIST, severe (NCI Grades 3/4) lab abnormalities (400 mg/day; 600 mg/day)--including neutropenia (10%; 11%), anemia (3%; 9%), thrombocytopenia (0%; 1%), and hepatotoxicity (6%; 8%)--and severe adverse experiences (NCI Grades 3/4), including severe fluid retention (eg, pleural effusion or ascites; 3%; 8%) and superficial edema (6%; 5%), hemorrhage (6%; 11%), abdominal pain (11%; 4%), nausea (6%; 4%), diarrhea (3%; 7%), and musculoskeletal pain (6%; 1%) were reported among patients receiving Gleevec.

Severe congestive heart failure and left ventricular dysfunction have occasionally been reported. Most of the patients with reported cardiac events have had other comorbidities and risk factors, including advanced age and previous medical history of cardiac disease. Patients with cardiac disease or risk factors for cardiac failure should be monitored carefully, and any patient with signs or symptoms consistent with cardiac failure should be evaluated and treated.

Dose adjustments may be necessary due to hepatotoxicity, other nonhematologic adverse reactions, or hematologic adverse reactions. Therapy with Gleevec was discontinued for drug-related adverse reaction
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults
2. Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)
3. Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study
4. Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib
5. Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results
6. Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
7. Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery
8. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
9. Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Dont Get Their Families Vaccinated
10. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
11. Video: Answer to Curing a Failing Heart May Exist in Bodys Own Do-It-Yourself Repair Kit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... September 23, 2014 Avillion ... the appointment of Jarrod Longcor as ... is responsible for structuring, negotiating and executing successful ... well as providing management and strategic leadership to ... Executive leadership team. Mr Longcor brings ...
(Date:9/22/2014)... , September 23, 2014 , ... health authorities, increasing rigor for trial master file (TMF) ... industry,s largest TMF survey to date reveals an increase ... to provide auditors with remote access to their electronic ... owners surveyed in the Veeva 2014 Paperless ...
(Date:9/22/2014)... Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ... $200 million of its common stock in an underwritten ... Merrill Lynch are acting as joint book-running managers for ... option to purchase additional shares of its common stock. ... offering are being sold by Avanir.  The offering is ...
Breaking Medicine Technology:Avillion Appoints Jarrod Longcor as Chief Business Officer 2Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 2Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 3Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 4Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 3
... March 15 URL Pharma, Inc. today announced the launch of an expanded ... eligible for low-cost Colcrys therapy. Uninsured and Medicare Part D patients with household incomes ... Colcrys PAP. This expanded program is available to patients immediately. , ... ...
... , March 15 Watson Pharmaceuticals, Inc. ... subsidiary, Watson Laboratories, Inc. – Florida , has ... (FDA) for its Abbreviated New Drug Application (ANDA) for ... Laboratories International SRL,s Cardizem® LA product.  Watson intends to ...
Cached Medicine Technology:URL Pharma Expands Colcrys(R) Patient Assistance Program 2URL Pharma Expands Colcrys(R) Patient Assistance Program 3URL Pharma Expands Colcrys(R) Patient Assistance Program 4URL Pharma Expands Colcrys(R) Patient Assistance Program 5URL Pharma Expands Colcrys(R) Patient Assistance Program 6Watson Receives FDA Approval for Generic Cardizem(R) LA 2Watson Receives FDA Approval for Generic Cardizem(R) LA 3
(Date:9/23/2014)... Sept. 23, 2014 (HealthDay News) -- The U.S. ... in additional funding in scientific trials to encourage ... clinical studies. The supplemental monies were provided ... including basic immunology, cardiovascular physiology, neural circuitry, and ... 23. "This funding strategy demonstrates our commitment ...
(Date:9/23/2014)... biology and a researcher in UTSA,s South Texas Center ... at Ruhr University in Bochum, Germany to understand how ... this week in an article published by the ... Cholera is an acute infection caused by ingestion of ... Vibrio cholerae . An estimated three to five ...
(Date:9/23/2014)... how living things function comes from knowledge of structuresatomic ... the receptors that are docking stations for viruses and ... that carry genetic blueprints for building cellular machinery, to ... these structural details, a new grant just awarded by ... Department of Energy (DOE) will fund the operation of ...
(Date:9/23/2014)... 23, 2014 If you or a ... for the treatment may be a challenge. Fortunately, an ... garment that is designed to improve the experience. , ... dialysis without having to remove, tear or reposition their ... and preserving their dignity. At the same time, it ...
(Date:9/23/2014)... has been shown to be a driving force ... often develops due to chronic inflammation caused by ... has relatively few effective treatment options. Now, scientists ... demonstrated for the first time in preclinical studies ... as astrocyte elevated gene-1 (AEG-1) halts the development ...
Breaking Medicine News(10 mins):Health News:NIH Adds $10M to Encourage Gender Balance in Clinical Trials 2Health News:UTSA microbiologists discover regulatory thermometer that controls cholera 2Health News:New NIH/DOE grant for life science studies at NSLS-II 2Health News:New NIH/DOE grant for life science studies at NSLS-II 3Health News:Apparel for Dialysis Patients Invented by InventHelp Client (CBA-2492) 2Health News:Study uncovers genetic driver of inflammation, uses it to prevent and treat liver cancer 2
... Smooth talking Mitt,Romney is back in Boston today, ... on the campaign trail. Asked by a reporter in ... health insurance to 3.8 million,uninsured children by expanding the ... vowed to do, Romney said "Yeah.,Yeah, I sure would." ...
... University of Manchester scientists will discuss their research aimed ... its effectiveness at the National Cancer Research Institute conference ... half of patients receive radiotherapy as part of their ... possibility of causing side effects (toxicity) to the normal ...
... Inherited condition can lead to sudden cardiac death ... with the heart drug perindopril, along with a ... of the hereditary disorder Marfan syndrome, research shows. ... is often characterized by excessive bone elongation and ...
... Studies Presented at EuroSpine are Among Several Demonstrating ... Minimally Invasive Procedure, AUSTIN, Texas, Oct. 2 ... be presented this week at EuroSpine in Brussels,found ... with contained,disc herniation. PDD is a minimally invasive ...
... 2 MedPage Today, the,innovative source of medical ... (CME) credit to physicians and other,clinicians, now provides ... (PAs) who complete CME activities on http://www.MedPageToday.com ... (AAPA), with a membership,of more than 40,000, is ...
... offer heart benefits , , TUESDAY, Oct. 2 (HealthDay News) -- ... makes resveratrol, a chemical found in the skin of red ... of diabetes and other conditions. , The study focused on ... effect that could lead to new treatments for type 2 ...
Cached Medicine News:Health News:DNC: Romney Chooses President Bush Over Uninsured Children 2Health News:DNC: Romney Chooses President Bush Over Uninsured Children 3Health News:Cancer researchers seek safe reduction of radiotherapy 2Health News:Drug Combo Helps Fight Marfan Syndrome 2Health News:New Studies Find Plasma Disc Decompression Effective for Contained Disc Herniation 2Health News:New Studies Find Plasma Disc Decompression Effective for Contained Disc Herniation 3Health News:New Studies Find Plasma Disc Decompression Effective for Contained Disc Herniation 4Health News:MedPage Today(R) Continuing Medical Education Activities Now Offer AAPA Credit for Physician Assistants 2Health News:Low Doses of Red Wine Chemical May Fight Diabetes 2
DS 7600 Central Station...
... MedSystem III DLE (Drug List Editor) Multi-Channel ... drug infusion technology. The instrument combines three ... clinical versatility in an unparalleled small size. ... MedSystem III Infusion System simplifies the delivery ...
... Freedom Chart Manager provides powerful workflow tools ... management, integrated transcription services, and customized flow ... that eliminates the need for paper charts. ... of a paperless office now and can ...
... ChartingPlus proves itself to over 2,000 ... Designed with the user in mind, ChartingPlus ... powerful and dynamic features to improve documentation ... practice. Our medical content is ...
Medicine Products: